Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyDavid S. Ettinger, Miranda Hughes, Aparna Hegde et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 1.4k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021David S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1k
Non–Small Cell Lung Cancer, Version 4.2024Gregory J. Riely, Lisa Hang, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 746
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023David S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2023Cited by 480
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancerDaniel Morgensztern, Pilar Garrido, Nina Karaseva et al.|Lung Cancer|2019Cited by 24